Paul Hartmann (PHH2) Q4 2024 earnings summary

Executive summary

• Achieved record adjusted EBITDA of €261.4m in 2024, up 28.6% year-over-year, driven by the ongoing transformation program and new product launches, despite challenging market conditions.

• Organic sales growth reached 2.6%, with total revenue at €2,407.9m, supported by gains in wound care, incontinence, and infection management segments.

• Net income rose to €113.7m, a 247% increase compared to the previous year, reflecting operational improvements and lower tax expenses.

• Proposed dividend of €8.00 per share, maintaining a long-standing policy of stable or rising payouts.

Financial highlights

• Revenue increased by 2.3% year-over-year to €2,407.9m; organic growth at 2.6%.

• Adjusted EBITDA rose to €261.4m (10.9% margin), up from €203.4m (8.6%) in 2023.

• Net income reached €113.7m, up from €32.7m in 2023; EPS at €30.53 versus €8.00 prior year.

• Free cash flow declined to €50.3m due to higher inventory and investment outflows.

• Equity ratio improved to 57.0% from 56.1% year-over-year.

Outlook and guidance

• Expects moderate organic sales growth and adjusted EBITDA between €260–300m for 2025.

• Transformation program to contribute an additional €50m to results in 2025.

• Plans to invest around €160m in production, IT, and sales infrastructure, with a focus on Germany and the US.

• Anticipates continued challenges in the German and European healthcare sectors, with low economic growth and ongoing cost pressures.